Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters Sells 60,743 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters sold 60,743 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $51.75, for a total transaction of $3,143,450.25. Following the transaction, the chief financial officer now directly owns 101,360 shares of the company’s stock, valued at approximately $5,245,380. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $50.01 on Friday. The firm has a market cap of $2.41 billion, a PE ratio of 25.65 and a beta of 0.84. Amphastar Pharmaceuticals, Inc. has a 52-week low of $26.76 and a 52-week high of $67.66. The company has a quick ratio of 1.11, a current ratio of 1.53 and a debt-to-equity ratio of 0.83. The company’s 50 day moving average is $57.02 and its two-hundred day moving average is $47.05.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Tuesday, August 8th. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. The company had revenue of $145.71 million for the quarter, compared to analyst estimates of $137.20 million. Amphastar Pharmaceuticals had a net margin of 18.85% and a return on equity of 20.12%. On average, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in AMPH. Envestnet Asset Management Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter valued at $238,000. Raymond James & Associates acquired a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter valued at $599,000. Bank of New York Mellon Corp raised its holdings in shares of Amphastar Pharmaceuticals by 8.2% in the 1st quarter. Bank of New York Mellon Corp now owns 401,405 shares of the company’s stock valued at $14,409,000 after purchasing an additional 30,462 shares in the last quarter. Citigroup Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 27.0% in the 1st quarter. Citigroup Inc. now owns 38,664 shares of the company’s stock valued at $1,388,000 after purchasing an additional 8,224 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Amphastar Pharmaceuticals by 2.9% in the 1st quarter. Bank of Montreal Can now owns 13,029 shares of the company’s stock valued at $477,000 after purchasing an additional 371 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AMPH. Piper Sandler increased their price objective on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a research report on Wednesday, August 9th. Jefferies Financial Group began coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, July 25th. They set a “buy” rating and a $70.00 price objective for the company. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).